Is Realty Income the Best Dividend Stock to Buy Long-Term?
Realty Income (NYSE:O) is a longstanding real estate investment trust…
Buy
64
BSX Quote, Financials, Valuation and Earnings
Last price:
$93.05
Seasonality move
:
5.74%
Day range:
$86.77 - $97.65
52-week range:
$66.80 - $107.17
Dividend yield:
0%
P/E ratio:
77.42x
P/S ratio:
8.59x
P/B ratio:
6.56x
Volume:
23.5M
Avg. volume:
9.6M
1-year change:
40.94%
Market cap:
$142.8B
Revenue:
$16.7B
EPS (TTM):
$1.25
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
BSX
Boston Scientific
|
$4.6B | $0.67 | 16.07% | 222.09% | $115.37 |
|
ABT
Abbott Laboratories
|
$10.4B | $1.07 | 5.86% | 68.83% | $136.47 |
|
MASI
Masimo
|
$367.8M | $1.21 | -25.37% | 192.38% | $195.70 |
|
PODD
Insulet
|
$543.2M | $0.78 | 23.07% | 6.17% | $312.92 |
|
RMD
ResMed
|
$1.3B | $2.36 | 7.21% | 15.65% | $269.42 |
|
SYK
Stryker
|
$5.7B | $2.73 | 8.46% | 47.47% | $423.15 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
BSX
Boston Scientific
|
$96.77 | $115.37 | $142.8B | 77.42x | $0.00 | 0% | 8.59x |
|
ABT
Abbott Laboratories
|
$127.04 | $136.47 | $220.3B | 16.61x | $0.59 | 1.76% | 5.29x |
|
MASI
Masimo
|
$164.57 | $195.70 | $8.9B | 116.80x | $0.00 | 0% | 4.25x |
|
PODD
Insulet
|
$264.72 | $312.92 | $18.6B | 45.72x | $0.00 | 0% | 9.44x |
|
RMD
ResMed
|
$216.44 | $269.42 | $31.8B | 25.55x | $0.53 | 0.96% | 6.48x |
|
SYK
Stryker
|
$362.97 | $423.15 | $138.5B | 46.77x | $0.84 | 0.9% | 6.19x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
BSX
Boston Scientific
|
32.79% | 0.797 | 8.05% | 0.46x |
|
ABT
Abbott Laboratories
|
22.86% | 0.777 | 7.72% | 1.23x |
|
MASI
Masimo
|
42.11% | 1.493 | 8.64% | 1.08x |
|
PODD
Insulet
|
53.47% | 1.438 | 7.6% | 2.50x |
|
RMD
ResMed
|
11.35% | 0.237 | 2% | 1.74x |
|
SYK
Stryker
|
39.72% | 1.207 | 10.13% | 1.11x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
BSX
Boston Scientific
|
$3.1B | $790M | 5.97% | 8.96% | 14.58% | $1.2B |
|
ABT
Abbott Laboratories
|
$6B | $1.9B | 24.06% | 32.63% | 19.74% | $2.1B |
|
MASI
Masimo
|
$244.7M | -$54.6M | -14.23% | -23.05% | -58.55% | $47.5M |
|
PODD
Insulet
|
$430.9M | $109.3M | 17.64% | 43.11% | 20.08% | $91.7M |
|
RMD
ResMed
|
$751.3M | $417.2M | 21.74% | 25.56% | 32.54% | $285.2M |
|
SYK
Stryker
|
$4.2B | $1.6B | 9.04% | 15.22% | 24.21% | $1.7B |
Boston Scientific vs. Competitors
-
Which has Higher Returns BSX or ABT?
Abbott Laboratories has a net margin of 12.41% compared to Boston Scientific's net margin of 84.1%. Boston Scientific's return on equity of 8.96% beat Abbott Laboratories's return on equity of 32.63%.
Company Gross Margin Earnings Per Share Invested Capital BSXBoston Scientific67.86% $0.38 $32.6B ABTAbbott Laboratories54.97% $5.27 $62B -
What do Analysts Say About BSX or ABT?
Boston Scientific has a consensus price target of $115.37, signalling upside risk potential of 19.22%. On the other hand Abbott Laboratories has an analysts' consensus of $136.47 which suggests that it could grow by 7.43%. Given that Boston Scientific has higher upside potential than Abbott Laboratories, analysts believe Boston Scientific is more attractive than Abbott Laboratories.
Company Buy Ratings Hold Ratings Sell Ratings BSXBoston Scientific23 5 0 ABTAbbott Laboratories13 7 0 -
Is BSX or ABT More Risky?
Boston Scientific has a beta of 0.728, which suggesting that the stock is 27.188% less volatile than S&P 500. In comparison Abbott Laboratories has a beta of 0.803, suggesting its less volatile than the S&P 500 by 19.666%.
-
Which is a Better Dividend Stock BSX or ABT?
Boston Scientific has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Abbott Laboratories offers a yield of 1.76% to investors and pays a quarterly dividend of $0.59 per share. Boston Scientific pays -- of its earnings as a dividend. Abbott Laboratories pays out 28.62% of its earnings as a dividend. Abbott Laboratories's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios BSX or ABT?
Boston Scientific quarterly revenues are $4.6B, which are smaller than Abbott Laboratories quarterly revenues of $11B. Boston Scientific's net income of $566M is lower than Abbott Laboratories's net income of $9.2B. Notably, Boston Scientific's price-to-earnings ratio is 77.42x while Abbott Laboratories's PE ratio is 16.61x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Boston Scientific is 8.59x versus 5.29x for Abbott Laboratories. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BSXBoston Scientific8.59x 77.42x $4.6B $566M ABTAbbott Laboratories5.29x 16.61x $11B $9.2B
-
Which has Higher Returns BSX or MASI?
Masimo has a net margin of 12.41% compared to Boston Scientific's net margin of -58.2%. Boston Scientific's return on equity of 8.96% beat Masimo's return on equity of -23.05%.
Company Gross Margin Earnings Per Share Invested Capital BSXBoston Scientific67.86% $0.38 $32.6B MASIMasimo40.74% -$6.52 $1.8B -
What do Analysts Say About BSX or MASI?
Boston Scientific has a consensus price target of $115.37, signalling upside risk potential of 19.22%. On the other hand Masimo has an analysts' consensus of $195.70 which suggests that it could grow by 18.91%. Given that Boston Scientific has higher upside potential than Masimo, analysts believe Boston Scientific is more attractive than Masimo.
Company Buy Ratings Hold Ratings Sell Ratings BSXBoston Scientific23 5 0 MASIMasimo4 3 0 -
Is BSX or MASI More Risky?
Boston Scientific has a beta of 0.728, which suggesting that the stock is 27.188% less volatile than S&P 500. In comparison Masimo has a beta of 1.278, suggesting its more volatile than the S&P 500 by 27.807%.
-
Which is a Better Dividend Stock BSX or MASI?
Boston Scientific has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Masimo offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Boston Scientific pays -- of its earnings as a dividend. Masimo pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BSX or MASI?
Boston Scientific quarterly revenues are $4.6B, which are larger than Masimo quarterly revenues of $600.7M. Boston Scientific's net income of $566M is higher than Masimo's net income of -$349.6M. Notably, Boston Scientific's price-to-earnings ratio is 77.42x while Masimo's PE ratio is 116.80x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Boston Scientific is 8.59x versus 4.25x for Masimo. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BSXBoston Scientific8.59x 77.42x $4.6B $566M MASIMasimo4.25x 116.80x $600.7M -$349.6M
-
Which has Higher Returns BSX or PODD?
Insulet has a net margin of 12.41% compared to Boston Scientific's net margin of 16.85%. Boston Scientific's return on equity of 8.96% beat Insulet's return on equity of 43.11%.
Company Gross Margin Earnings Per Share Invested Capital BSXBoston Scientific67.86% $0.38 $32.6B PODDInsulet72.12% $1.39 $2.6B -
What do Analysts Say About BSX or PODD?
Boston Scientific has a consensus price target of $115.37, signalling upside risk potential of 19.22%. On the other hand Insulet has an analysts' consensus of $312.92 which suggests that it could grow by 18.21%. Given that Boston Scientific has higher upside potential than Insulet, analysts believe Boston Scientific is more attractive than Insulet.
Company Buy Ratings Hold Ratings Sell Ratings BSXBoston Scientific23 5 0 PODDInsulet14 4 0 -
Is BSX or PODD More Risky?
Boston Scientific has a beta of 0.728, which suggesting that the stock is 27.188% less volatile than S&P 500. In comparison Insulet has a beta of 1.300, suggesting its more volatile than the S&P 500 by 30.008%.
-
Which is a Better Dividend Stock BSX or PODD?
Boston Scientific has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insulet offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Boston Scientific pays -- of its earnings as a dividend. Insulet pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BSX or PODD?
Boston Scientific quarterly revenues are $4.6B, which are larger than Insulet quarterly revenues of $597.5M. Boston Scientific's net income of $566M is higher than Insulet's net income of $100.7M. Notably, Boston Scientific's price-to-earnings ratio is 77.42x while Insulet's PE ratio is 45.72x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Boston Scientific is 8.59x versus 9.44x for Insulet. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BSXBoston Scientific8.59x 77.42x $4.6B $566M PODDInsulet9.44x 45.72x $597.5M $100.7M
-
Which has Higher Returns BSX or RMD?
ResMed has a net margin of 12.41% compared to Boston Scientific's net margin of 26.88%. Boston Scientific's return on equity of 8.96% beat ResMed's return on equity of 25.56%.
Company Gross Margin Earnings Per Share Invested Capital BSXBoston Scientific67.86% $0.38 $32.6B RMDResMed58.6% $2.34 $5.9B -
What do Analysts Say About BSX or RMD?
Boston Scientific has a consensus price target of $115.37, signalling upside risk potential of 19.22%. On the other hand ResMed has an analysts' consensus of $269.42 which suggests that it could grow by 24.48%. Given that ResMed has higher upside potential than Boston Scientific, analysts believe ResMed is more attractive than Boston Scientific.
Company Buy Ratings Hold Ratings Sell Ratings BSXBoston Scientific23 5 0 RMDResMed8 6 1 -
Is BSX or RMD More Risky?
Boston Scientific has a beta of 0.728, which suggesting that the stock is 27.188% less volatile than S&P 500. In comparison ResMed has a beta of 0.755, suggesting its less volatile than the S&P 500 by 24.514%.
-
Which is a Better Dividend Stock BSX or RMD?
Boston Scientific has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ResMed offers a yield of 0.96% to investors and pays a quarterly dividend of $0.53 per share. Boston Scientific pays -- of its earnings as a dividend. ResMed pays out 27.65% of its earnings as a dividend. ResMed's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios BSX or RMD?
Boston Scientific quarterly revenues are $4.6B, which are larger than ResMed quarterly revenues of $1.3B. Boston Scientific's net income of $566M is higher than ResMed's net income of $344.6M. Notably, Boston Scientific's price-to-earnings ratio is 77.42x while ResMed's PE ratio is 25.55x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Boston Scientific is 8.59x versus 6.48x for ResMed. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BSXBoston Scientific8.59x 77.42x $4.6B $566M RMDResMed6.48x 25.55x $1.3B $344.6M
-
Which has Higher Returns BSX or SYK?
Stryker has a net margin of 12.41% compared to Boston Scientific's net margin of 8.48%. Boston Scientific's return on equity of 8.96% beat Stryker's return on equity of 15.22%.
Company Gross Margin Earnings Per Share Invested Capital BSXBoston Scientific67.86% $0.38 $32.6B SYKStryker64.85% $1.41 $34.2B -
What do Analysts Say About BSX or SYK?
Boston Scientific has a consensus price target of $115.37, signalling upside risk potential of 19.22%. On the other hand Stryker has an analysts' consensus of $423.15 which suggests that it could grow by 16.58%. Given that Boston Scientific has higher upside potential than Stryker, analysts believe Boston Scientific is more attractive than Stryker.
Company Buy Ratings Hold Ratings Sell Ratings BSXBoston Scientific23 5 0 SYKStryker13 9 0 -
Is BSX or SYK More Risky?
Boston Scientific has a beta of 0.728, which suggesting that the stock is 27.188% less volatile than S&P 500. In comparison Stryker has a beta of 0.929, suggesting its less volatile than the S&P 500 by 7.107%.
-
Which is a Better Dividend Stock BSX or SYK?
Boston Scientific has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Stryker offers a yield of 0.9% to investors and pays a quarterly dividend of $0.84 per share. Boston Scientific pays -- of its earnings as a dividend. Stryker pays out 40.73% of its earnings as a dividend. Stryker's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios BSX or SYK?
Boston Scientific quarterly revenues are $4.6B, which are smaller than Stryker quarterly revenues of $6.4B. Boston Scientific's net income of $566M is higher than Stryker's net income of $546M. Notably, Boston Scientific's price-to-earnings ratio is 77.42x while Stryker's PE ratio is 46.77x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Boston Scientific is 8.59x versus 6.19x for Stryker. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BSXBoston Scientific8.59x 77.42x $4.6B $566M SYKStryker6.19x 46.77x $6.4B $546M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Archer Aviation a Buy, Sell or Hold?
Vertical takeoff and landing (eVTOL) aircraft sound futuristic but that’s…
Down 50%, Is Dell Technologies a Buy?
Dell (NYSE:DELL)’s share price has been on a roller coaster…
Stock Ideas
Sell
43
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Buy
53
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $2.8T
P/E Ratio: 39x
Alerts
Sell
33
BULZ alert for Apr 10
MicroSectors Solactive FANG & Innov 3X Levd ETN [BULZ] is down 15.35% over the past day.
Sell
31
TECS alert for Apr 10
Direxion Daily Technology Bear 3x Shares [TECS] is up 12.66% over the past day.
Sell
48
FNGA alert for Apr 10
MicroSectors FANG+ Index 3X Leveraged ETN [FNGA] is down 13.3% over the past day.
